Matches in SemOpenAlex for { <https://semopenalex.org/work/W2439226702> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2439226702 endingPage "1068" @default.
- W2439226702 startingPage "1061" @default.
- W2439226702 abstract "The humanized KS-interleukin-2, tucotuzumab (huKS-IL2; EMD 273066), is an EpCAM-specific immunocytokine with reported immunologic activity in combination with cyclophosphamide. This Phase 2, randomized, open-label study compared tucotuzumab/cyclophosphamide, administered as maintenance, with best supportive care (BSC) in patients with extensive-disease small-cell lung cancer (ED-SCLC) who responded to first-line platinum-based chemotherapy with/without prophylactic cranial irradiation (PCI). Patients received cyclophosphamide (300 mg/m2, Day 1 of every 3-week cycle), followed by tucotuzumab (1.5 mg/m2, Days 2–4) until disease progression. The primary endpoint was 6-month progression-free survival (PFS); the secondary objectives included overall survival (OS), treatment response, and safety. The 6-month PFS rate was lower in the tucotuzumab/cyclophosphamide group (n=64) than in the BSC group (n=44): 6.4 versus 12.2% [hazard ratio (HR): 0.98; 80% confidence interval (CI): 0.74–1.31]. HRs for PFS, time to progression, and OS indicated a similar risk of disease progression and death in both groups and best overall responses were generally comparable. For patients with previous PCI (n=26), there was a nonsignificant trend toward prolonged median PFS (1.7 vs. 1.5 months; HR: 0.60; 80% CI: 0.33–1.11) and OS (21.5 vs. 14.3 months; HR: 0.58; 80% CI: 0.31–1.05) in the tucotuzumab/cyclophosphamide group. Adverse events were more frequent with tucotuzumab/cyclophosphamide (92.2%) than with BSC (47.7%). Tucotuzumab/cyclophosphamide was well tolerated in ED-SCLC patients, but did not show PFS or OS benefits compared with BSC. The observed trend toward prolonged PFS and OS in the subgroup of patients receiving previous PCI may support further confirmation in a larger population." @default.
- W2439226702 created "2016-06-24" @default.
- W2439226702 creator A5013730320 @default.
- W2439226702 creator A5033776778 @default.
- W2439226702 creator A5037659742 @default.
- W2439226702 creator A5037860810 @default.
- W2439226702 creator A5061233442 @default.
- W2439226702 creator A5073572288 @default.
- W2439226702 creator A5073935596 @default.
- W2439226702 creator A5087508872 @default.
- W2439226702 date "2015-11-01" @default.
- W2439226702 modified "2023-10-16" @default.
- W2439226702 title "Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer" @default.
- W2439226702 cites W1984484474 @default.
- W2439226702 cites W1990676527 @default.
- W2439226702 cites W2012075312 @default.
- W2439226702 cites W2032517155 @default.
- W2439226702 cites W2062080828 @default.
- W2439226702 cites W2105471629 @default.
- W2439226702 cites W2111708038 @default.
- W2439226702 cites W2111921907 @default.
- W2439226702 cites W2131664752 @default.
- W2439226702 cites W2132836850 @default.
- W2439226702 cites W2134557975 @default.
- W2439226702 cites W2138683149 @default.
- W2439226702 cites W2146605445 @default.
- W2439226702 cites W2152819527 @default.
- W2439226702 cites W2154323253 @default.
- W2439226702 cites W2162533394 @default.
- W2439226702 cites W2339444986 @default.
- W2439226702 doi "https://doi.org/10.1097/cad.0000000000000281" @default.
- W2439226702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26295868" @default.
- W2439226702 hasPublicationYear "2015" @default.
- W2439226702 type Work @default.
- W2439226702 sameAs 2439226702 @default.
- W2439226702 citedByCount "11" @default.
- W2439226702 countsByYear W24392267022016 @default.
- W2439226702 countsByYear W24392267022018 @default.
- W2439226702 countsByYear W24392267022019 @default.
- W2439226702 countsByYear W24392267022020 @default.
- W2439226702 countsByYear W24392267022021 @default.
- W2439226702 countsByYear W24392267022022 @default.
- W2439226702 countsByYear W24392267022023 @default.
- W2439226702 crossrefType "journal-article" @default.
- W2439226702 hasAuthorship W2439226702A5013730320 @default.
- W2439226702 hasAuthorship W2439226702A5033776778 @default.
- W2439226702 hasAuthorship W2439226702A5037659742 @default.
- W2439226702 hasAuthorship W2439226702A5037860810 @default.
- W2439226702 hasAuthorship W2439226702A5061233442 @default.
- W2439226702 hasAuthorship W2439226702A5073572288 @default.
- W2439226702 hasAuthorship W2439226702A5073935596 @default.
- W2439226702 hasAuthorship W2439226702A5087508872 @default.
- W2439226702 hasConcept C126322002 @default.
- W2439226702 hasConcept C141071460 @default.
- W2439226702 hasConcept C143998085 @default.
- W2439226702 hasConcept C168563851 @default.
- W2439226702 hasConcept C197934379 @default.
- W2439226702 hasConcept C203092338 @default.
- W2439226702 hasConcept C207103383 @default.
- W2439226702 hasConcept C2776256026 @default.
- W2439226702 hasConcept C2776694085 @default.
- W2439226702 hasConcept C2776755627 @default.
- W2439226702 hasConcept C44249647 @default.
- W2439226702 hasConcept C71924100 @default.
- W2439226702 hasConcept C90924648 @default.
- W2439226702 hasConceptScore W2439226702C126322002 @default.
- W2439226702 hasConceptScore W2439226702C141071460 @default.
- W2439226702 hasConceptScore W2439226702C143998085 @default.
- W2439226702 hasConceptScore W2439226702C168563851 @default.
- W2439226702 hasConceptScore W2439226702C197934379 @default.
- W2439226702 hasConceptScore W2439226702C203092338 @default.
- W2439226702 hasConceptScore W2439226702C207103383 @default.
- W2439226702 hasConceptScore W2439226702C2776256026 @default.
- W2439226702 hasConceptScore W2439226702C2776694085 @default.
- W2439226702 hasConceptScore W2439226702C2776755627 @default.
- W2439226702 hasConceptScore W2439226702C44249647 @default.
- W2439226702 hasConceptScore W2439226702C71924100 @default.
- W2439226702 hasConceptScore W2439226702C90924648 @default.
- W2439226702 hasIssue "10" @default.
- W2439226702 hasLocation W24392267021 @default.
- W2439226702 hasLocation W24392267022 @default.
- W2439226702 hasOpenAccess W2439226702 @default.
- W2439226702 hasPrimaryLocation W24392267021 @default.
- W2439226702 hasRelatedWork W1989798994 @default.
- W2439226702 hasRelatedWork W2213433074 @default.
- W2439226702 hasRelatedWork W2340130805 @default.
- W2439226702 hasRelatedWork W2375646327 @default.
- W2439226702 hasRelatedWork W2413020017 @default.
- W2439226702 hasRelatedWork W2556093218 @default.
- W2439226702 hasRelatedWork W2601574680 @default.
- W2439226702 hasRelatedWork W2765995209 @default.
- W2439226702 hasRelatedWork W3163691534 @default.
- W2439226702 hasRelatedWork W4306253774 @default.
- W2439226702 hasVolume "26" @default.
- W2439226702 isParatext "false" @default.
- W2439226702 isRetracted "false" @default.
- W2439226702 magId "2439226702" @default.
- W2439226702 workType "article" @default.